Clinical Trials Logo
  1. Home
  2. Streptococcus Pneumoniae
  3. NCT00814489

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Streptococcus Pneumoniae Clinical Trial

Official title:
A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in young adults. Subjects will be vaccinated 2 times in an observer-blind manner with an interval of 2 months. The subjects receiving Engerix-B will receive in an open-manner a third dose of the vaccine at Month 6. The protocol posting has been updated following a protocol amendment.

Clinical Trial Description

This Protocol Posting has been updated following amendment of the Protocol, January 2010. The sections impacted are: study design and study endpoints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00814489
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date January 8, 2009
Completion date June 10, 2010
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT02215863 - Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Phase 4
Completed NCT01521897 - Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) N/A
Completed NCT00197769 - Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants Phase 2
Completed NCT02888457 - Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Centers N/A
Completed NCT01995617 - Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine Phase 1
Completed NCT01425372 - Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
Completed NCT00594347 - Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar Phase 3
Completed NCT00861380 - Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease Phase 3
Active, not recruiting NCT00900978 - Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants Phase 1/Phase 2
Completed NCT00814710 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age Phase 3
Suspended NCT01308827 - Costa Rica Epidemiological Study on S. Pneumoniae N/A
Recruiting NCT04078997 - An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
Terminated NCT00849069 - Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine Phase 1
Recruiting NCT06096025 - Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Completed NCT00907777 - Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ Phase 3
Completed NCT00273325 - Immunogenicity of PCV-7 Vaccine in VLBW Infants
Completed NCT01730391 - Neisseria Meningitidis Burden of Disease Study N/A
Completed NCT00197821 - Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Phase 2
Completed NCT00839254 - Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Phase 3